0

Close
 
Upcoming Allied Market Research
2023
Crispr Cas9 Gene Editing Market

CRISPR Cas9 Gene Editing Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

LS : Diagnostics and Biotech
Report Code: A10468
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Crispr Cas9 Gene Editing Market

Request Now !

CRISPR Cas9 Gene Editing Market Outlook - 2027

CRISPR gene editing is a genetic engineering technique in molecular biology by which the genomes of living organisms may be modified. It is based on a simplified version of the bacterial CRISPR-Cas9 antiviral defense system. By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added in vivo (in living organisms). The technique is considered highly significant in biotechnology and medicine as it allows for the genomes to be edited in vivo with extremely high precision and with ease. It can be used in the creation of new medicines, agricultural products, and genetically modified organisms, or as a means of controlling pathogens and pests. It also has possibilities in the treatment of inherited genetic diseases as well as diseases arising from somatic mutations such as cancer.

CRISPR-Cas9-Gene-Editing

COVID-19 scenario analysis: 

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat with the COVID-19 outbreak, from supporting the development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are kept in the R&D pipeline in the coming years. Moreover, commonly used drugs, such as hydroxychloroquine, have witnessed huge boost in demand for the management of COVID-19. There is an increase in demand for drugs,, which presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Attributed to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors: Market scenario analysis, trends, drivers, and impact analysis

The major factor affecting the industry includes growth in technological advancements in the gene editing platform. This is anticipated to help the industry propel in the coming years. Furthermore, there has been up gradation in newer versions of the protein such as eSpCas9 and SpCas9-HF. This has been engineered to reduce off-target editing activity without the requirement for two sgRNAs. There has been increase in research activities for new enzymes, proteins, gRNA engineering, and off-target detection methods, which are the need of the hour; hence, these would help the industry grow at a rapid pace in the coming years. Additionally, anti-CRISPR has been introduced in the market, which opens up the CRISPR Cas9 gene editing market and is expected to gain higher revenue in the coming years.

Growth in the number of product launches to boost the market

The surge in the number of product launches in recent years is anticipated to help the industry flourish. For instance, in September 2016, GenScript, a global provider of gene synthesis services, launched its most versatile CRISPR service, synthetic CRISPR RNAs (crRNA). This new addition complements its already extensive CRISPR service and product portfolio. Until now, CRISPR constructs have been DNA-based, carrying a risk of insertional mutagenesis, off-target effects, and toxic delivery into stem cells and primary cells. By working immediately after delivery into the cell, the synthetic CRISPR ribonucleoproteins results in quick DNA editing and rapid cell clearance with fewer off-target risks. 

GenScript’s CRISPR RNAs expand gene-editing to even more research applications. CRISPR RNA, when combined with tracrRNA and Cas9 protein, forms a ribonucleoprotein (RNP) complex that is capable of efficient and effective gene editing. As a part of GenScript’s new synthetic crRNA service, customers are able to pick from Broad Institute-validated crRNA sequences or custom sequences that are then synthesized and pre-duplexed to tracrRNA at GenScript. Once received by customers, the crRNA:tracrRNA sequences are complexed with Cas9 protein prior to delivery into cells or embryos, such as mouse and zebrafish, with no synthesis or in vitro transcription required.

Surge in number of mergers & acquisitions to propel the market

Mergers & acquisitions are anticipated to boost the industry in the coming years. For instance, in November 2020, PerkinElmer expanded its life sciences portfolio with CRISPR and gene editing offerings by snapping up the cell engineering specialist Horizon Discovery. The $383 million, all-cash deal will add gene modulation tools in combination with its own work in applied genomics solutions, which aims to provide
next-generation research tools and customized cell lines necessary for developers of new targeted therapies, and broaden PerkinElmer’s partnership work with academic researchers and the biopharma industry.

The Cambridge, U.K.-based Horizon, with about 400 employees worldwide and offices in the U.S. and Japan, provides genetic base editing technologies for living cell models using CRISPR reagents as well as gene modulation products using RNA interference methods.

Key benefits of the report:

  • This study presents the analytical depiction of the global CRISPR Cas9 gene editing market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global CRISPR Cas9 gene editing market share.
  • The current market is quantitatively analyzed to highlight the global CRISPR Cas9 gene editing market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global CRISPR Cas9 gene editing market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the market research report:

  • Which are the leading market players active in the market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in taking further strategic steps?

 CRISPR Cas9 Gene Editing Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights

Aspects Details
By Product & Service
  • Kits & Enzymes
  • Vector-based Cas
  • DNA-free Cas
  • Antibodies
  • Libraries
  • Design Tool
  • Cell Line Engineering
  • gRNA Design
  • Microbial Gene Editing
  • DNA Synthesis
  • Others
By Application
  • Biomedical
  • Genome Engineering
  • Disease Model Studies
  • Functional Genomics
  • Epigenetics
  • Agricultural
  • Others
By End User
  • Biotechnology & Pharmaceutical Companies
  • Academics & Government Research Institutes
  • Contract Research Organizations (CROs)
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Merck KGaA,, Caribou Biosciences, Inc.,, Egenesis,, CRISPR Therapeutics,, Cellectis,, AstraZeneca,, F. Hoffmann-La Roche Ltd.,, Danaher Corporation,, Takara Bio, Inc., Genscrip,, Addgene,, Horizon Discovery Group Plc,, Editas Medicine, Inc.,
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: CRISPR CAS9 GENE EDITING MARKET, BY PRODUCT SERVICE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Service

    • 4.2. Kits Enzymes

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Vector-based Cas

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. DNA-free Cas

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Antibodies

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Libraries

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Design Tool

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Cell Line Engineering

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. GRNA Design

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

    • 4.10. Microbial Gene Editing

      • 4.10.1. Key Market Trends, Growth Factors and Opportunities

      • 4.10.2. Market Size and Forecast, By Region

      • 4.10.3. Market Share Analysis, By Country

    • 4.11. DNA Synthesis

      • 4.11.1. Key Market Trends, Growth Factors and Opportunities

      • 4.11.2. Market Size and Forecast, By Region

      • 4.11.3. Market Share Analysis, By Country

    • 4.12. Others

      • 4.12.1. Key Market Trends, Growth Factors and Opportunities

      • 4.12.2. Market Size and Forecast, By Region

      • 4.12.3. Market Share Analysis, By Country

  • CHAPTER 5: CRISPR CAS9 GENE EDITING MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Biomedical

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Genome Engineering

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Disease Model Studies

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Functional Genomics

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Epigenetics

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Agricultural

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Others

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

  • CHAPTER 6: CRISPR CAS9 GENE EDITING MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Biotechnology Pharmaceutical Companies

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Academics Government Research Institutes

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Contract Research Organizations (CROs)

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: CRISPR CAS9 GENE EDITING MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product Service

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Crispr Cas9 Gene Editing Market

        • 7.2.6.1. Market Size and Forecast, By Product Service
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Crispr Cas9 Gene Editing Market

        • 7.2.7.1. Market Size and Forecast, By Product Service
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Crispr Cas9 Gene Editing Market

        • 7.2.8.1. Market Size and Forecast, By Product Service
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product Service

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Crispr Cas9 Gene Editing Market

        • 7.3.6.1. Market Size and Forecast, By Product Service
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Crispr Cas9 Gene Editing Market

        • 7.3.7.1. Market Size and Forecast, By Product Service
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Crispr Cas9 Gene Editing Market

        • 7.3.8.1. Market Size and Forecast, By Product Service
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Crispr Cas9 Gene Editing Market

        • 7.3.9.1. Market Size and Forecast, By Product Service
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Crispr Cas9 Gene Editing Market

        • 7.3.10.1. Market Size and Forecast, By Product Service
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Crispr Cas9 Gene Editing Market

        • 7.3.11.1. Market Size and Forecast, By Product Service
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Crispr Cas9 Gene Editing Market

        • 7.3.12.1. Market Size and Forecast, By Product Service
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product Service

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Crispr Cas9 Gene Editing Market

        • 7.4.6.1. Market Size and Forecast, By Product Service
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Crispr Cas9 Gene Editing Market

        • 7.4.7.1. Market Size and Forecast, By Product Service
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Crispr Cas9 Gene Editing Market

        • 7.4.8.1. Market Size and Forecast, By Product Service
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Crispr Cas9 Gene Editing Market

        • 7.4.9.1. Market Size and Forecast, By Product Service
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Crispr Cas9 Gene Editing Market

        • 7.4.10.1. Market Size and Forecast, By Product Service
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Crispr Cas9 Gene Editing Market

        • 7.4.11.1. Market Size and Forecast, By Product Service
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Crispr Cas9 Gene Editing Market

        • 7.4.12.1. Market Size and Forecast, By Product Service
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Crispr Cas9 Gene Editing Market

        • 7.4.13.1. Market Size and Forecast, By Product Service
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Crispr Cas9 Gene Editing Market

        • 7.4.14.1. Market Size and Forecast, By Product Service
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product Service

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Crispr Cas9 Gene Editing Market

        • 7.5.6.1. Market Size and Forecast, By Product Service
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Crispr Cas9 Gene Editing Market

        • 7.5.7.1. Market Size and Forecast, By Product Service
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Crispr Cas9 Gene Editing Market

        • 7.5.8.1. Market Size and Forecast, By Product Service
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Crispr Cas9 Gene Editing Market

        • 7.5.9.1. Market Size and Forecast, By Product Service
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Crispr Cas9 Gene Editing Market

        • 7.5.10.1. Market Size and Forecast, By Product Service
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Crispr Cas9 Gene Editing Market

        • 7.5.11.1. Market Size and Forecast, By Product Service
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. CRISPR Therapeutics,

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. AstraZeneca,

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Addgene,

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Caribou Biosciences, Inc.,

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Cellectis,

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Editas Medicine, Inc.,

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Egenesis,

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. F. Hoffmann-La Roche Ltd.,

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Horizon Discovery Group Plc,

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Genscrip,

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Danaher Corporation,

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

    • 9.12. Merck KGaA,

      • 9.12.1. Company Overview

      • 9.12.2. Key Executives

      • 9.12.3. Company Snapshot

      • 9.12.4. Operating Business Segments

      • 9.12.5. Product Portfolio

      • 9.12.6. Business Performance

      • 9.12.7. Key Strategic Moves and Developments

    • 9.13. Takara Bio, Inc.

      • 9.13.1. Company Overview

      • 9.13.2. Key Executives

      • 9.13.3. Company Snapshot

      • 9.13.4. Operating Business Segments

      • 9.13.5. Product Portfolio

      • 9.13.6. Business Performance

      • 9.13.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CRISPR CAS9 GENE EDITING MARKET, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR KITS ENZYMES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR VECTOR-BASED CAS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR DNA-FREE CAS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR ANTIBODIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR LIBRARIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR DESIGN TOOL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR GRNA DESIGN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR MICROBIAL GENE EDITING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR DNA SYNTHESIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL CRISPR CAS9 GENE EDITING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR BIOMEDICAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR GENOME ENGINEERING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR DISEASE MODEL STUDIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR FUNCTIONAL GENOMICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR EPIGENETICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR AGRICULTURAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL CRISPR CAS9 GENE EDITING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR BIOTECHNOLOGY PHARMACEUTICAL COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR ACADEMICS GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. GLOBAL CRISPR CAS9 GENE EDITING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2022-2032 ($MILLION)
  • TABLE 25. GLOBAL CRISPR CAS9 GENE EDITING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA CRISPR CAS9 GENE EDITING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 28. NORTH AMERICA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. NORTH AMERICA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. U.S. CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 31. U.S. CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. U.S. CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. CANADA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 34. CANADA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. CANADA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. MEXICO CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE CRISPR CAS9 GENE EDITING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. EUROPE CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. GERMANY CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. ITALY CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 50. ITALY CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. ITALY CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. UK CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 56. UK CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. UK CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. RUSSIA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 59. RUSSIA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. RUSSIA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. REST OF EUROPE CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. ASIA-PACIFIC CRISPR CAS9 GENE EDITING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. CHINA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 69. CHINA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. CHINA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 72. JAPAN CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. JAPAN CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. INDIA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 75. INDIA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. INDIA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. SOUTH KOREA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 78. SOUTH KOREA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 79. SOUTH KOREA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. AUSTRALIA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 81. AUSTRALIA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 82. AUSTRALIA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. THAILAND CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 84. THAILAND CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. THAILAND CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. MALAYSIA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 87. MALAYSIA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. MALAYSIA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. INDONESIA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 90. INDONESIA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 91. INDONESIA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 92. REST OF ASIA PACIFIC CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 93. REST OF ASIA PACIFIC CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 94. REST OF ASIA PACIFIC CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA CRISPR CAS9 GENE EDITING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 97. LAMEA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 98. LAMEA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. BRAZIL CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 100. BRAZIL CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 101. BRAZIL CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. SOUTH AFRICA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 103. SOUTH AFRICA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 104. SOUTH AFRICA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 105. SAUDI ARABIA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 106. SAUDI ARABIA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 107. SAUDI ARABIA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 108. UAE CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 109. UAE CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 110. UAE CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. ARGENTINA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 112. ARGENTINA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 113. ARGENTINA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA CRISPR CAS9 GENE EDITING, BY PRODUCT SERVICE, 2022-2032 ($MILLION)
  • TABLE 115. REST OF LAMEA CRISPR CAS9 GENE EDITING, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 116. REST OF LAMEA CRISPR CAS9 GENE EDITING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 117. CRISPR THERAPEUTICS,: KEY EXECUTIVES
  • TABLE 118. CRISPR THERAPEUTICS,: COMPANY SNAPSHOT
  • TABLE 119. CRISPR THERAPEUTICS,: OPERATING SEGMENTS
  • TABLE 120. CRISPR THERAPEUTICS,: PRODUCT PORTFOLIO
  • TABLE 121. CRISPR THERAPEUTICS,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. ASTRAZENECA,: KEY EXECUTIVES
  • TABLE 123. ASTRAZENECA,: COMPANY SNAPSHOT
  • TABLE 124. ASTRAZENECA,: OPERATING SEGMENTS
  • TABLE 125. ASTRAZENECA,: PRODUCT PORTFOLIO
  • TABLE 126. ASTRAZENECA,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. ADDGENE,: KEY EXECUTIVES
  • TABLE 128. ADDGENE,: COMPANY SNAPSHOT
  • TABLE 129. ADDGENE,: OPERATING SEGMENTS
  • TABLE 130. ADDGENE,: PRODUCT PORTFOLIO
  • TABLE 131. ADDGENE,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. CARIBOU BIOSCIENCES, INC.,: KEY EXECUTIVES
  • TABLE 133. CARIBOU BIOSCIENCES, INC.,: COMPANY SNAPSHOT
  • TABLE 134. CARIBOU BIOSCIENCES, INC.,: OPERATING SEGMENTS
  • TABLE 135. CARIBOU BIOSCIENCES, INC.,: PRODUCT PORTFOLIO
  • TABLE 136. CARIBOU BIOSCIENCES, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. CELLECTIS,: KEY EXECUTIVES
  • TABLE 138. CELLECTIS,: COMPANY SNAPSHOT
  • TABLE 139. CELLECTIS,: OPERATING SEGMENTS
  • TABLE 140. CELLECTIS,: PRODUCT PORTFOLIO
  • TABLE 141. CELLECTIS,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. EDITAS MEDICINE, INC.,: KEY EXECUTIVES
  • TABLE 143. EDITAS MEDICINE, INC.,: COMPANY SNAPSHOT
  • TABLE 144. EDITAS MEDICINE, INC.,: OPERATING SEGMENTS
  • TABLE 145. EDITAS MEDICINE, INC.,: PRODUCT PORTFOLIO
  • TABLE 146. EDITAS MEDICINE, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. EGENESIS,: KEY EXECUTIVES
  • TABLE 148. EGENESIS,: COMPANY SNAPSHOT
  • TABLE 149. EGENESIS,: OPERATING SEGMENTS
  • TABLE 150. EGENESIS,: PRODUCT PORTFOLIO
  • TABLE 151. EGENESIS,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. F. HOFFMANN-LA ROCHE LTD.,: KEY EXECUTIVES
  • TABLE 153. F. HOFFMANN-LA ROCHE LTD.,: COMPANY SNAPSHOT
  • TABLE 154. F. HOFFMANN-LA ROCHE LTD.,: OPERATING SEGMENTS
  • TABLE 155. F. HOFFMANN-LA ROCHE LTD.,: PRODUCT PORTFOLIO
  • TABLE 156. F. HOFFMANN-LA ROCHE LTD.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. HORIZON DISCOVERY GROUP PLC,: KEY EXECUTIVES
  • TABLE 158. HORIZON DISCOVERY GROUP PLC,: COMPANY SNAPSHOT
  • TABLE 159. HORIZON DISCOVERY GROUP PLC,: OPERATING SEGMENTS
  • TABLE 160. HORIZON DISCOVERY GROUP PLC,: PRODUCT PORTFOLIO
  • TABLE 161. HORIZON DISCOVERY GROUP PLC,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. GENSCRIP,: KEY EXECUTIVES
  • TABLE 163. GENSCRIP,: COMPANY SNAPSHOT
  • TABLE 164. GENSCRIP,: OPERATING SEGMENTS
  • TABLE 165. GENSCRIP,: PRODUCT PORTFOLIO
  • TABLE 166. GENSCRIP,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 167. DANAHER CORPORATION,: KEY EXECUTIVES
  • TABLE 168. DANAHER CORPORATION,: COMPANY SNAPSHOT
  • TABLE 169. DANAHER CORPORATION,: OPERATING SEGMENTS
  • TABLE 170. DANAHER CORPORATION,: PRODUCT PORTFOLIO
  • TABLE 171. DANAHER CORPORATION,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 172. MERCK KGAA,: KEY EXECUTIVES
  • TABLE 173. MERCK KGAA,: COMPANY SNAPSHOT
  • TABLE 174. MERCK KGAA,: OPERATING SEGMENTS
  • TABLE 175. MERCK KGAA,: PRODUCT PORTFOLIO
  • TABLE 176. MERCK KGAA,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. TAKARA BIO, INC.: KEY EXECUTIVES
  • TABLE 178. TAKARA BIO, INC.: COMPANY SNAPSHOT
  • TABLE 179. TAKARA BIO, INC.: OPERATING SEGMENTS
  • TABLE 180. TAKARA BIO, INC.: PRODUCT PORTFOLIO
  • TABLE 181. TAKARA BIO, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CRISPR CAS9 GENE EDITING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CRISPR CAS9 GENE EDITING MARKET
  • FIGURE 3. SEGMENTATION CRISPR CAS9 GENE EDITING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CRISPR CAS9 GENE EDITING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCRISPR CAS9 GENE EDITING MARKET
  • FIGURE 11. CRISPR CAS9 GENE EDITING MARKET SEGMENTATION, BY BY PRODUCT SERVICE
  • FIGURE 12. CRISPR CAS9 GENE EDITING MARKET FOR KITS ENZYMES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. CRISPR CAS9 GENE EDITING MARKET FOR VECTOR-BASED CAS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. CRISPR CAS9 GENE EDITING MARKET FOR DNA-FREE CAS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. CRISPR CAS9 GENE EDITING MARKET FOR ANTIBODIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. CRISPR CAS9 GENE EDITING MARKET FOR LIBRARIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. CRISPR CAS9 GENE EDITING MARKET FOR DESIGN TOOL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. CRISPR CAS9 GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. CRISPR CAS9 GENE EDITING MARKET FOR GRNA DESIGN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. CRISPR CAS9 GENE EDITING MARKET FOR MICROBIAL GENE EDITING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. CRISPR CAS9 GENE EDITING MARKET FOR DNA SYNTHESIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. CRISPR CAS9 GENE EDITING MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. CRISPR CAS9 GENE EDITING MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 24. CRISPR CAS9 GENE EDITING MARKET FOR BIOMEDICAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. CRISPR CAS9 GENE EDITING MARKET FOR GENOME ENGINEERING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. CRISPR CAS9 GENE EDITING MARKET FOR DISEASE MODEL STUDIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. CRISPR CAS9 GENE EDITING MARKET FOR FUNCTIONAL GENOMICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. CRISPR CAS9 GENE EDITING MARKET FOR EPIGENETICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. CRISPR CAS9 GENE EDITING MARKET FOR AGRICULTURAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. CRISPR CAS9 GENE EDITING MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. CRISPR CAS9 GENE EDITING MARKET SEGMENTATION, BY BY END USER
  • FIGURE 32. CRISPR CAS9 GENE EDITING MARKET FOR BIOTECHNOLOGY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 33. CRISPR CAS9 GENE EDITING MARKET FOR ACADEMICS GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 34. CRISPR CAS9 GENE EDITING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 35. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 36. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 37. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 38. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 39. COMPETITIVE DASHBOARD
  • FIGURE 40. COMPETITIVE HEATMAP: CRISPR CAS9 GENE EDITING MARKET
  • FIGURE 41. Top player positioning, 2022
  • FIGURE 42. CRISPR THERAPEUTICS,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. CRISPR THERAPEUTICS,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. CRISPR THERAPEUTICS,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. ASTRAZENECA,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. ASTRAZENECA,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. ASTRAZENECA,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. ADDGENE,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. ADDGENE,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. ADDGENE,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. CARIBOU BIOSCIENCES, INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. CARIBOU BIOSCIENCES, INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. CARIBOU BIOSCIENCES, INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. CELLECTIS,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. CELLECTIS,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. CELLECTIS,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. EDITAS MEDICINE, INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. EDITAS MEDICINE, INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. EDITAS MEDICINE, INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. EGENESIS,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. EGENESIS,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. EGENESIS,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. F. HOFFMANN-LA ROCHE LTD.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. F. HOFFMANN-LA ROCHE LTD.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. F. HOFFMANN-LA ROCHE LTD.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 66. HORIZON DISCOVERY GROUP PLC,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. HORIZON DISCOVERY GROUP PLC,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 68. HORIZON DISCOVERY GROUP PLC,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 69. GENSCRIP,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. GENSCRIP,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 71. GENSCRIP,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 72. DANAHER CORPORATION,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 73. DANAHER CORPORATION,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 74. DANAHER CORPORATION,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 75. MERCK KGAA,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 76. MERCK KGAA,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 77. MERCK KGAA,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 78. TAKARA BIO, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 79. TAKARA BIO, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 80. TAKARA BIO, INC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Crispr Cas9 Gene Editing Market

Start reading.
This Report and over 67,112+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers